Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. - Wikidata - awgldk - TriplyDB

Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.

Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.

http://www.wikidata.org/entity/Q40302879

about

Pulmonary Hypertension and Indicators of Right Ventricular Function Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)Is cardiac resynchronization therapy for right ventricular failure in pulmonary arterial hypertension of benefit?DNA Damage and Pulmonary Hypertension Right ventricular adaptation and failure in pulmonary arterial hypertension.PET Metabolic Biomarkers for Cancer Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension New Biochemical Insights into the Mechanisms of Pulmonary Arterial Hypertension in Humans Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.Coronary Bypass Surgery in Patients with Pulmonary Hypertension: Assessment of Early and Long Term Results.PLS-Based and Regularization-Based Methods for the Selection of Relevant Variables in Non-targeted Metabolomics Data Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.New trial designs and potential therapies for pulmonary artery hypertension.Coenzyme Q supplementation in pulmonary arterial hypertension.Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1 Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.Mitochondrial dynamics in pulmonary arterial hypertension.Right ventricular long noncoding RNA expression in human heart failure Diagnosing and treating the failing right heart.Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung.Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.Metabolic Dysfunction in Pulmonary Arterial Hypertension.Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model.Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension Evolving targeted therapies for right ventricular failure.Novel investigational therapies for treating pulmonary arterial hypertension.Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease.Novel assessment of haemodynamic kinetics with acute exercise in a rat model of pulmonary arterial hypertension.Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development.Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes.Cardiac manifestations of mitochondrial disorders Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.Right ventricular end-diastolic stiffness heralds right ventricular failure in monocrotaline-induced pulmonary hypertension.Treatment strategies for the right heart in pulmonary hypertension.Current Knowledge and Recent Advances of Right Ventricular Molecular Biology and Metabolism from Congenital Heart Disease to Chronic Pulmonary Hypertension.Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.

P2860

Q26744781-2D49D4E9-1FC0-43AE-91CA-3F7C7ADC2CB5 Q26772286-66047F96-D366-46B1-B7E8-66E371C62E2B Q26829301-05E26947-BA6D-4F0F-886C-3E55C8FCE074 Q27005594-51E7C2BA-BBC9-4575-B622-3F6E3731346E Q27318422-5B5E625A-8C7E-4591-BCE1-36D27A0AFE4C Q28074449-71FD4E96-0D09-4C47-AB33-4C81E1C0D31E Q28083183-6D07EA18-DB44-4D61-82A8-3B418546D09B Q28553362-77B66250-8202-4236-BA3A-B036AB91B16D Q28602210-5211CE7E-B89F-43FE-80D6-8123FB200A09 Q30248878-80FB8A2A-6BB4-450A-B627-511DAA4DF3F8 Q30373733-57CF7632-CB1E-49E6-9F98-B906892386F0 Q31120773-04F43B85-AF16-4E91-8EE2-2C852EF48BFB Q33608219-CA8F2647-2C09-4498-82DA-99ABC4E55F63 Q33982467-A86C848C-8CAF-4491-B3BC-B9CF7AE6099D Q34085977-86219374-7D5D-4DC1-A9BA-7A5F99DF78B3 Q34178976-7A7F9BE9-C4AB-4C7D-B045-074F7FE4BBDC Q34356167-3F35EE70-95D3-4EB5-B540-4C23F81C3359 Q35116543-052DA78C-9FC9-464F-A9C2-B4D7139D8547 Q35517383-CA84C94F-9391-4B60-A003-81578CAD8DBB Q35599768-C54096AB-8C03-460E-89B5-8D9FB81F0D98 Q35944064-27825256-EF35-4084-A12C-CF4C83AA7ECA Q36016535-7536408E-25B0-47DE-B87B-F300B90AB9BF Q36752368-4CC148D0-6FFF-4C0D-A2F7-5EE40C99D7D9 Q36825335-6DFAFA2B-C643-4A87-8798-1EB20735A874 Q37003895-27889BD2-1C65-4DA9-965D-1A5A95B87C9E Q37217460-531EED64-7CB0-4A15-B15B-564F64B53417 Q38559308-D45277FD-2F7C-4196-8B5A-6646A9217551 Q38612061-65C60045-4BB1-48EC-ACEE-2BDC10F916F6 Q38828821-0D75857E-0D1C-4EC1-A810-957D510D4537 Q39018693-E83CC8B0-DEBB-4B21-955C-B0176C180032 Q39317865-3E8AFC3D-8BCF-4CD3-BC80-D6035B75736E Q41022731-0ECEE59C-A4C0-418D-A067-E2420B857C35 Q42707021-1C337F5B-CFA9-416F-9570-8E8436AB92F3 Q42840047-E35303E1-0F42-4308-8C50-B867BE4478E2 Q46273115-3361A471-8438-4050-AD77-E880105944C4 Q46980824-9D9CF4DD-CE1A-4139-85B7-1FCD1A944F63 Q47622646-759222CB-EBE9-48E6-9359-B289F9C0D6C3 Q52629104-D6D7F8B5-CCA7-4A08-B77A-50B7EFEBF98D Q53842649-963072B7-E584-42E5-9820-95B5ACBA783A

P2860

Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.

http://www.wikidata.org/entity/Q40302879

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Metabolism and bioenergetics i ...... ure in pulmonary hypertension.

@en

type

label

Metabolism and bioenergetics i ...... ure in pulmonary hypertension.

@en

prefLabel

Metabolism and bioenergetics i ...... ure in pulmonary hypertension.

@en

P1433

Q40302879-20D40B6A-F9D7-415E-AC10-BD3E530A1648

P1476

Q40302879-442D9CBC-57D2-49D3-A5C6-0834001305B7

P2093

Q40302879-11B66B84-95E9-4D98-B0E7-E42FFDBB8DEF

Q40302879-403C64E5-6108-4078-ADBA-3E3B9A1C275E

Q40302879-475D85E4-3766-409B-946D-8E819D901691

Q40302879-B8D26031-DA49-4873-B3EB-25D7872BF25B

P2860

Q40302879-04D11F14-62EA-4D40-8339-12766445631F

Q40302879-09F5D582-B9D8-43FD-98DA-A0906D9B59D0

Q40302879-0B112824-C75C-406A-A2CD-346CD59BE64C

Q40302879-0D82605F-6A25-4D6C-9193-6EF12C2FF104

Q40302879-0EE29225-4DA6-4E54-BE7B-F10259DD8CAC

Q40302879-122C779D-A939-495E-AAE4-F26156205EBB

Q40302879-13CDE257-C9B6-4623-983F-08B6AF388514

Q40302879-17F1B8F3-A703-4E17-BC6E-166F4AECD86D

Q40302879-1ADC97D6-4630-4116-8301-EC6933C37543

Q40302879-1E045F7C-59E9-4DB0-BF64-65E1295E7965

P304

Q40302879-64AB2869-B911-49E0-B51E-55589DC0EC0F

P31

Q40302879-5110063F-C639-44D5-96A4-F45E6EC0B1CC

P356

Q40302879-C712C58E-81E6-4892-8975-D52DCAEE607C

P433

Q40302879-94570F64-FE15-4FAC-9004-8CA4B2F5A497

P478

Q40302879-D1E396BD-6F24-49F7-B6B3-01BD4C6E9859

P577

Q40302879-4E7DABE2-6465-493B-B9B0-735867F40AF6

P5875

Q40302879-4E44F963-DE4E-409C-A021-2907180CF62B

P698

Q40302879-F8237F51-0B3F-434A-8474-5FEE964E85B0

P932

Q40302879-68BFFD8A-142F-4302-8BC4-A3685AEE614B

P356

2045-8932.109960

P1433

Pulmonary circulation

P1476

Metabolism and bioenergetics i ...... ure in pulmonary hypertension.

@en

P2093

John J Ryan

http://www.w3.org/2001/XMLSchema#string

Lin Piao

http://www.w3.org/2001/XMLSchema#string

Stephen L Archer

http://www.w3.org/2001/XMLSchema#string

Yong-Hu Fang

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology

Metabolic modulation of glioblastoma with dichloroacetate

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload

Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha

P304

144-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2045-8932.109960

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236676269

http://www.w3.org/2001/XMLSchema#string

P698

23662191

http://www.w3.org/2001/XMLSchema#string

P932

3641722

http://www.w3.org/2001/XMLSchema#string